Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas

Cytometry Part B - Clinical Cytometry

Volumn 64, Issue 1, 2005, Pages 43-52

  Leers, M P G ^a   Hoop, J G M ^a   Van Beers, M ^a   Van Rodijnen, N ^a   Pannebakker, M ^a   Nap, M ^a  

^a Zuyderland Medical Centre   (Netherlands)

Author keywords

Cytokeratin; Estrogen receptor; Flow cytometry; Mammary carcinoma; Ploidy; Progesterone receptor

Indexed keywords

CYTOKERATIN; ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CELL CYCLE; CELL SUSPENSION; CONTROLLED STUDY; DIPLOIDY; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TETRAPLOIDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODES; MIDDLE AGED; NEOPLASM STAGING; PARAFFIN EMBEDDING; PLOIDIES; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; REFERENCE VALUES; SEER PROGRAM;

EID: 21844472780     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.20045     Document Type: Article

References (27)

1. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-2877.
2. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:154-155.
3. Ravdin PM. A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy. Hematol Oncol Clin North Am 1994;8:197-211.
4. Rayter Z. Steroid receptors in breast cancer. Br J Surg 1991;78:528-535.
5. Nicholson RI, McClelland RA, Gee JM. Steroid hormone receptors and their clinical significance in cancer. J Clin Pathol 1995;48:890-895.
6. Hendricks JB, Wilkinson EJ. Comparison of two antibodies for evaluation of estrogen receptors in paraffin-embedded tumors. Mod Pathol 1993;6:765-770.
7. al Saati T, Clamens S, Cohen-Knafo E, Faye JC, Prats H, Coindre JM, Wafflart J, Cayeriviere P, Bayard F, Delsol G. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer 1993;55:651-654.
8. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-130.
9. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG, Miller KD. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001;115:44-58.
10. Masood S. The story of hormone receptor assays: why are we still searching? Breast J 2001;7:205-206.
11. Leers MP, Schutte B, Theunissen PH, Ramaekers FC, Nap M. A novel flow cytometric steroid hormone receptor assay for paraffin-embedded breast carcinomas: an objective quantification of the steroid hormone receptors and direct correlation to ploidy status and proliferative capacity in a single-tube assay [In Process Citation]. Hum Pathol 2000;31:584-592.
12. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 2001;19:18-27.
13. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-696.
14. Bloom HJGRW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.
15. UICC. TNM classification of malignant tumors. 5th edition. Berlin: Springer-Verlag; 1997.
16. Leers MP, Schutte B, Theunissen PH, Ramaekers FC, Nap M. Heat pretreatment increases resolution in DNA flow cytometry of paraffin-embedded tumor tissue. Cytometry 1999;35:260-266.
17. Saccani Jotti G, Johnston SR, Salter J, Detre S, Dowsett M, Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol 1994;47:900-905.
18. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-1451.
19. Allred DC, Bustamunte MA, Daniel CO, Gaskili HV, Cruz AB Jr. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125:107-113.
20. Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, Tuchler H. A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat 1995;36:11-21.
21. Hanna W, McReady DR, Chapman JW, Mobbs BG, Trudeau ME. The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis. Mod Pathol 1993;6:748-754.
22. Beck T, Weikel W, Brumm C, Wilkens C, Follow K, Knapstein PG. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 1994;53:220-227.
23. Mirza NA, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235: 10-26.
24. Leers MP, Nap M. Steroid receptor heterogeneity in relation to DNA index in breast cancer: a multiparameter flow cytometric approach on paraffin-embedded tumor samples. Breast J 2001;7:249-259.
25. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folson AR. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995;4:319-326.
26. Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol 1988;27:1-19.
27. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer 1984; 53:630-643.